Greg Yap

Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Prior to Menlo, Greg spent 20 years as an executive and entrepreneur in life science and digital health. He was CEO/co-founder of two startups: BlueLight Therapeutics/Biodesy and PyrAmes. At Roche Diagnostics/Ventana, Greg led a $500 million cancer diagnostic assay business. Greg also served as VP/GM for genetics and molecular diagnostics at Affymetrix, entrepreneur-in-residence at both Illumina Ventures and GE, and consultant for McKinsey. Greg received his AB in molecular biology (summa cum laude) from Princeton and his MBA from Stanford. He is an Aspen Health Innovators Fellow and member of the Aspen Global Leadership Network. He also serves on the board of Outward Bound California.